Clinical Trial Update: AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating AK104 with AK112 and SOX/XELOX chemotherapy as first-line treatment for advanced gastric and gastroesophageal junction cancer. The…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• AK104 (PD-1/CTLA-4 bispecific antibody)
• AK112

Snippet

Sponsor: Harbin Medical University | Conditions: Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Status: RECRUITING